Listed

Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2024

Filed with the SEC on Aug 9, 2024 and accepted by EDGAR at Aug 9, 2024, 16:27 ET.

Share

Management's discussion and analysis

As filed, 42,850 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals. We operate principally in the United States (“U.S.”), India, and Ireland, and sell to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. Risk Factors in our 2023 Annual Report on Form 10-K and under the heading Cautionary Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three and six months ended June 30, 2024 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.

Overview

We have three reportable segments: Generics, Specialty, and AvKARE.

Generics

Our Generics segment includes approximately 270 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches and topicals. We focus on developing products with substantial barriers-to-entry due to complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on our financial results. The entrance into the market of additional competition generally has a negative impact on the volume and/or pricing of the affected products. Additionally, pricing is determined by market place dynamics and is often affected by factors outside of our control.

Specialty

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system (“CNS”) disorders, including Parkinson’s disease, and endocrine disorders. Our portfolio of products includes RYTARY®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to RYTARY®, our promoted Specialty portfolio also includes UNITHROID® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc., and ONGENTYS® (opicapone), an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes, which we commenced selling in early 2024 under a license agreement with BIAL-Portela & Ca., S.A.

On August 7, 2024, the FDA approved the Company’s new drug application for IPX203, which will be marketed under the trade name CREXONT®. CREXONT® is a combination of carbidopa and levodopa extended-release capsules, indicated for the treatment of Parkinson’s disease. The Company expects to make CREXONT® available to patients in the U.S. in September 2024.

Our Specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Our Specialty segment also has a number of product candidates that are in varying stages of development.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S., when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

AvKARE

Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our 2023 Annual Report on Form 10-K, as supplemented by Part II, Item 1A “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q.

Inflation

While it is difficult to accurately measure the impact of inflation, we estimate our business will experience an increase in costs due to inflation of approximately $10.0 million to $15.0 million for the year ending December 31, 2024, excluding the impact of rising interest rates. Notwithstanding our estimates, rising inflationary pressures due to higher input costs, including higher material, transportation, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.

Results of Operations

Comparison of Three Months Ended June 30, 2024 to Three Months Ended June 30, 2023

Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three months ended June 30, 2024 and 2023 (in thousands):

Three Months Ended June 30, 2024 2023 Increase (Decrease) $%
Net revenue $701,780 $599,046 $102,734 17.1%
Cost of goods sold 451,833 379,025 72,808 19.2%
Gross profit 249,947 220,021 29,926 13.6%
Selling, general and administrative 116,462 105,570 10,892 10.3%
Research and development 36,054 37,799 (1,745) (4.6)%
Intellectual property legal development expenses 1,042 820 222 27.1%
Restructuring and other charges 220 82 138 nm
Change in fair value of contingent consideration — (6,364) 6,364 nm
Charges related to legal matters, net 699 2,017 (1,318) (65.3)%
Other operating income — 13 (13) nm
Operating income 95,470 80,084 15,386 19.2%
Total other expense, net (75,065) (50,424) (24,641) 48.9%
Income before income taxes 20,405 29,660 (9,255) (31.2)%
Provision for (benefit from) income taxes 3,618 (23) 3,641 nm
Net income $16,787 $29,683 $(12,896) (43.4)%

nm - not meaningful

Net Revenue

Net revenue for the three months ended June 30, 2024 increased 17.1% from the prior year period primarily due to:

  • Growth in our Generics segment net revenue of $53.6 million, primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $16.7 million of year-over-year growth and other new generic products that contributed $36.2 million of year-over-year growth, and strong volume growth.
  • Growth in our AvKARE segment net revenue of $42.1 million, primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.
  • Growth in our Specialty segment net revenue of $7.0 million, primarily driven by a $9.4 million increase in our promoted neurology portfolio, of which $3.5 million was comprised of sales of ONGENTYS®, which launched during the first quarter of 2024, and growth in our promoted endocrinology portfolio of $2.7 million, partially offset by declines in our non-promoted products.

Cost of Goods Sold and Gross Profit

Cost of goods sold increased 19.2% for the three months ended June 30, 2024 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased AvKARE and Generics volume and increased plant and freight costs, partially offset by efficiencies in our supply costs.

Gross profit as a percentage of net revenue decreased to 35.6% for the three months ended June 30, 2024 from 36.7% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Selling, general, and administrative (“SG&A”) expenses for the three months ended June 30, 2024 increased 10.3% as compared to the prior year period primarily due to increases in employee compensation, promotion associated with ONGENTYS® and our planned launch of IPX203, and costs associated with growth in biosimilar revenues.

Research and Development

Research and development (“R&D”) expenses for the three months ended June 30, 2024 decreased 4.6% as compared to the prior year period primarily due to a decrease in in-licensing and upfront milestone payments of $0.7 million and operating efficiencies in our infrastructure.

Change in Fair Value of Contingent Consideration

Refer to Note 15. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $6.4 million change in the fair value of contingent consideration for the three months ended June 30, 2023 was primarily driven by a decrease in the associated forecasted revenues.

Total Other Expense, Net

Total other expense, net for the three months ended June 30, 2024 increased 48.9% as compared to the prior year period. The increase was primarily driven by a $14.9 million increase in interest expense as a result of higher rates on our variable-rate debt and an increase in the amount outstanding on our revolving credit facility and a $13.0 million increase in our tax receivable agreement liability (refer to Note 5. Income Taxes for additional information), partially offset by a gain on the sale of a subsidiary in India of $3.8 million (refer to Note 19. Related Party Transactions for additional information).

Provision For (Benefit From) Income Taxes

For the three months ended June 30, 2024, our provision for income taxes and effective tax rate were $3.6 million and 17.7%, respectively. For the three months ended June 30, 2023, the Company’s benefit from income taxes and effective tax rate were both immaterial. The period-over-period changes in the provision for income taxes and effective tax rate were primarily related to changes in the jurisdictional mix of income.

Generics

The following table sets forth results of operations for our Generics segment for the three months ended June 30, 2024 and 2023 (in thousands):

Three Months Ended June 30, 2024 2023 Increase (Decrease) $%
Net revenue $427,328 $373,701 $53,627 14.4%
Cost of goods sold 260,903 225,189 35,714 15.9%
Gross profit 166,425 148,512 17,913 12.1%
Selling, general and administrative 31,627 28,040 3,587 12.8%
Research and development 31,703 31,108 595 1.9%
Intellectual property legal development expenses 1,032 801 231 28.8%
Restructuring and other charges 53 — 53 nm
Charges related to legal matters, net 699 2,017 (1,318) (65.3)%
Other operating income — 13 (13) nm
Operating income $101,311 $86,533 $14,778 17.1%

nm - not meaningful

Net Revenue

Generics net revenue for the three months ended June 30, 2024 increased 14.4% as compared to the prior year period primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $16.7 million of year-over-year growth and other new generic products that contributed $36.2 million of year-over-year growth, and strong volume growth.

Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the three months ended June 30, 2024 increased 15.9% as compared to the prior year period primarily due to costs associated with increased sales volume and increased plant and freight costs, partially offset by efficiencies in our supply costs.

Generics gross profit as a percentage of net revenue decreased to 38.9% for the three months ended June 30, 2024 from 39.7% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Generics SG&A expense for the three months ended June 30, 2024 increased 12.8% as compared to the prior year period primarily due to increases in employee compensation driven by infrastructure expansion and promotion associated with our biosimilars.

Research and Development

Generics R&D expenses for the three months ended June 30, 2024 increased 1.9% as compared to the prior year period primarily due to an increase in project spend of $1.0 million, partially offset by a decrease in in-licensing and upfront milestone payments.

Specialty

The following table sets forth results of operations for our Specialty segment for the three months ended June 30, 2024 and 2023 (in thousands):

Three Months Ended June 30, 2024 2023 Increase (Decrease) $%
Net revenue $104,041 $96,994 $7,047 7.3%
Cost of goods sold 46,142 46,512 (370) (0.8)%
Gross profit 57,899 50,482 7,417 14.7%
Selling, general and administrative 26,610 22,759 3,851 16.9%
Research and development 4,351 6,691 (2,340) (35.0)%
Intellectual property legal development expenses 10 19 (9) (47.4)%
Restructuring and other charges 78 82 (4) (4.9)%
Change in fair value of contingent consideration — (6,364) 6,364 nm
Operating income $26,850 $27,295 $(445) (1.6)%

nm - not meaningful

Net Revenue

Specialty net revenue for the three months ended June 30, 2024 increased 7.3% compared to the prior year period, primarily driven by a $9.4 million increase in our promoted neurology portfolio, of which $3.5 million was comprised of sales of ONGENTYS®, which launched during the first quarter of 2024, and growth in our promoted endocrinology portfolio of $2.7 million, partially offset by declines in our non-promoted products.

Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended June 30, 2024 was flat compared to the prior year period, as growth in promoted products was offset by declines in our lower margin non-promoted products. Specialty gross profit as a percentage of net revenue increased to 55.7% for the three months ended June 30, 2024 as compared to 52.0% in the prior year period due to growth in our higher margin promoted products.

Selling, General, and Administrative

Specialty SG&A expense for the three months ended June 30, 2024 increased 16.9% as compared to the prior year period primarily due to increases in promotional costs associated with ONGENTYS® and our planned launch of IPX203.

Research and Development

Specialty R&D expenses for the three months ended June 30, 2024 decreased 35.0% as compared to the prior year period primarily due to reduced project spend of $1.1 million and reduced infrastructure costs.

Change in Fair Value of Contingent Consideration

Refer to Note 15. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $6.4 million change in the fair value of contingent consideration for the three months ended June 30, 2023 was primarily driven by a decrease in the associated forecasted revenues.

AvKARE

The following table sets forth results of operations for our AvKARE segment for the three months ended June 30, 2024 and 2023 (in thousands):

Three Months Ended June 30, 2024 2023 Increase $%
Net revenue $170,411 $128,351 $42,060 32.8%
Cost of goods sold 144,788 107,324 37,464 34.9%
Gross profit 25,623 21,027 4,596 21.9%
Selling, general and administrative 14,642 14,015 627 4.5%
Operating income $10,981 $7,012 $3,969 56.6%

Net Revenue

AvKARE net revenue for the three months ended June 30, 2024 increased 32.8% as compared to the prior year period primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.

Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the three months ended June 30, 2024 increased 34.9% as compared to the prior year period, and gross profit as a percentage of net revenue decreased to 15.0% for the three months ended June 30, 2024 from 16.4% in the prior year period, primarily due to the increase in sales through our lower margin distribution channel.

Selling, General and Administrative

AvKARE SG&A expense for the three months ended June 30, 2024 increased 4.5% as compared to the prior year period primarily due to higher sales-related expenses and professional fees, partially offset by reduced logistic costs.

Comparison of Six Months Ended June 30, 2024 to Six Months Ended June 30, 2023

Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the six months ended June 30, 2024 and 2023 (in thousands):

Six Months Ended June 30, 2024 2023 Increase (Decrease) $%
Net revenue $1,360,971 $1,156,586 $204,385 17.7%
Cost of goods sold 872,964 758,379 114,585 15.1%
Gross profit 488,007 398,207 89,800 22.6%
Selling, general and administrative 229,057 207,666 21,391 10.3%
Research and development 75,352 76,489 (1,137) (1.5)%
Intellectual property legal development expenses 2,026 2,464 (438) (17.8)%
Restructuring and other charges 1,690 592 1,098 nm
Change in fair value of contingent consideration 100 (3,907) 4,007 nm
Charges related to legal matters, net 95,058 1,581 93,477 nm
Other operating income — (1,211) 1,211 nm
Operating income 84,724 114,533 (29,809) (26.0)%
Total other expense, net (139,841) (94,299) (45,542) 48.3%
(Loss) income before income taxes (55,117) 20,234 (75,351) nm
Provision for income taxes 9,774 645 9,129 nm
Net (loss) income $(64,891) $19,589 $(84,480) nm

41 nm - not meaningful

Net Revenue

Net revenue for the six months ended June 30, 2024 increased 17.7% from the prior year period primarily due to:

  • Growth in our Generics segment net revenue of $101.1 million, primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $41.3 million of year-over-year growth and other new generic products that contributed $55.4 million of year-over-year growth, and strong volume growth. Net revenue for the six months ended June 30, 2023 included a non-recurring customer order of $21.0 million.
  • Growth in our AvKARE segment net revenue of $82.7 million, primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.
  • Growth in our Specialty segment net revenue of $20.6 million, primarily driven by an $18.8 million increase in our promoted neurology portfolio, of which $7.5 million was comprised of sales of ONGENTYS®, which launched during the first quarter of 2024, and growth in our promoted endocrinology portfolio of $7.3 million, partially offset by declines in our non-promoted products.

Cost of Goods Sold and Gross Profit

Cost of goods sold increased 15.1% for the six months ended June 30, 2024 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased AvKARE and Generics volume and increased plant and freight costs, partially offset by efficiencies in our supply costs. Cost of goods sold for the six months ended June 30, 2023 included $11.0 million associated with the non-recurring customer order in our Generics segment discussed above.

Gross profit as a percentage of net revenue increased to 35.9% for the six months ended June 30, 2024 from 34.4% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

SG&A expenses for the six months ended June 30, 2024 increased 10.3% as compared to the prior year period primarily due to increases in employee compensation, promotion associated with ONGENTYS® and our planned launch of IPX203, charges associated with our growing biosimilars, and annual fees assessed on branded prescription drug manufacturers, which are also applicable to certain of our generic products.

Research and Development

R&D expenses for the six months ended June 30, 2024 decreased 1.5% as compared to the prior year period primarily due to lower project spend of $1.4 million and operating efficiencies in our infrastructure, partially offset by an increase in in-licensing and upfront milestone payments of $2.8 million.

Change in Fair Value of Contingent Consideration

Refer to Note 15. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $3.9 million change in the fair value of contingent consideration for the six months ended June 30, 2023 was primarily driven by a decrease in the associated forecasted revenues.

Charges Related to Legal Matters, Net

For the six months ended June 30, 2024, charges related to legal matters, net of $95.1 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the U.S. Refer to Note 17. Commitments and Contingencies for additional information.

Total Other Expense, Net

Total other expense, net for the six months ended June 30, 2024 increased 48.3% as compared to the prior year period. The increase was primarily driven by a $31.3 million increase in interest expense as a result of higher rates on our variable-rate debt and an increase in the amount outstanding on our revolving credit facility and a $14.2 million increase in our tax receivable agreement liability (refer to Note 5. Income Taxes for additional information), partially offset by a gain on the sale of a subsidiary in India of $3.8 million (refer to Note 19. Related Party Transactions for additional information).

Provision For Income Taxes

For the six months ended June 30, 2024, our provision for income taxes and effective tax rate were $9.8 million and (17.7)%, respectively, as compared to a provision for income taxes and effective tax rate of $0.6 million and 3.2%, respectively, for the six months ended June 30, 2023. The period-over-period changes in the provision for income taxes and effective tax rate primarily related to changes in the jurisdictional mix of income.

Generics

The following table sets forth results of operations for our Generics segment for the six months ended June 30, 2024 and 2023 (in thousands):

Six Months Ended June 30, 2024 2023 Increase (Decrease) $%
Net revenue $818,622 $717,507 $101,115 14.1%
Cost of goods sold 500,825 455,740 45,085 9.9%
Gross profit 317,797 261,767 56,030 21.4%
Selling, general and administrative 64,712 55,640 9,072 16.3%
Research and development 66,074 63,467 2,607 4.1%
Intellectual property legal development expenses 1,992 2,425 (433) (17.9)%
Restructuring and other charges 53 99 (46) (46.5)%
Charges (credit) related to legal matters, net 95,058 (427) 95,485 nm
Other operating income — (1,211) 1,211 nm
Operating income $89,908 $141,774 $(51,866) (36.6)%

nm - not meaningful

Net Revenue

Generics net revenue for the six months ended June 30, 2024 increased 14.1% as compared to the prior year period primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $41.3 million of year-over-year growth and other new generic products that contributed $55.4 million of year-over-year growth, and strong volume growth. Net revenue for the six months ended June 30, 2023 included a non-recurring customer order of $21.0 million.

Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the six months ended June 30, 2024 increased 9.9% as compared to the prior year period primarily due to costs associated with increased sales volume and increased plant and freight costs, partially offset by efficiencies in our supply costs. Cost of goods sold for the six months ended June 30, 2023 included $11.0 million associated with the non-recurring customer order discussed above.

Generics gross profit as a percentage of net revenue increased to 38.8% for the six months ended June 30, 2024 from 36.5% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Generics SG&A expense for the six months ended June 30, 2024 increased 16.3% as compared to the prior year period primarily due to increases in employee compensation driven by infrastructure expansion and promotion associated with our biosimilar launches and the annual fees assessed on branded prescription drug manufacturers.

Research and Development

Generics R&D expenses for the six months ended June 30, 2024 increased 4.1% as compared to the prior year period primarily due to an increase in in-licensing and upfront milestone payments of $2.8 million.

Charges (Credit) Related to Legal Matters, Net

For the six months ended June 30, 2024, charges related to legal matters, net of $95.1 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the U.S. Refer to Note 17. Commitments and Contingencies for additional information.

Specialty

The following table sets forth results of operations for our Specialty segment for the six months ended June 30, 2024 and 2023 (in thousands):

Six Months Ended June 30, 2024 2023 Increase (Decrease) $%
Net revenue $209,275 $188,672 $20,603 10.9%
Cost of goods sold 90,942 89,703 1,239 1.4%
Gross profit 118,333 98,969 19,364 19.6%
Selling, general and administrative 51,806 45,138 6,668 14.8%
Research and development 9,278 13,022 (3,744) (28.8)%
Intellectual property legal development expenses 34 39 (5) (12.8)%
Restructuring and other charges 1,024 82 942 nm
Change in fair value of contingent consideration 100 (3,907) 4,007 nm
Operating income $56,091 $44,595 $11,496 25.8%

nm - not meaningful

Net Revenue

Specialty net revenue for the six months ended June 30, 2024 increased 10.9% as compared to the prior year period, primarily driven by an $18.8 million increase in our promoted neurology portfolio, of which $7.5 million was comprised of sales of ONGENTYS®, which launched during the first quarter of 2024, and growth in our promoted endocrinology portfolio of $7.3 million, partially offset by declines in our non-promoted products.

Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the six months ended June 30, 2024 increased 1.4% as compared to the prior year period, primarily due to growth in our promoted products, partially offset by declines in our lower margin non-promoted products. Specialty gross profit as a percentage of net revenue increased to 56.5% for the six months ended June 30, 2024 as compared to 52.5% in the prior year period due to growth in our higher margin promoted products.

Selling, General, and Administrative

Specialty SG&A expense for the six months ended June 30, 2024 increased 14.8% as compared to the prior year period primarily due to increases in promotional costs associated with ONGENTYS® and our planned launch of IPX203 and an increase in the annual fees assessed on branded prescription drug manufacturers.

Research and Development

Specialty R&D expenses for the six months ended June 30, 2024 decreased 28.8% as compared to the prior year period primarily due to reduced project spend of $1.7 million and reduced infrastructure costs.

Change in Fair Value of Contingent Consideration

Refer to Note 15. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $3.9 million change in the fair value of contingent consideration for the six months ended June 30, 2023 was primarily driven by a decrease in the associated forecasted revenues.

AvKARE

The following table sets forth results of operations for our AvKARE segment for the six months ended June 30, 2024 and 2023 (in thousands):

Six Months Ended June 30, 2024 2023 Increase $%
Net revenue $333,074 $250,407 $82,667 33.0%
Cost of goods sold 281,197 212,936 68,261 32.1%
Gross profit 51,877 37,471 14,406 38.4%
Selling, general and administrative 29,549 26,955 2,594 9.6%
Operating income $22,328 $10,516 $11,812 112.3%

Net Revenue

AvKARE net revenue for the six months ended June 30, 2024 increased 33.0% as compared to the prior year period primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.

Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the six months ended June 30, 2024 increased 32.1% as compared to the prior year period, and gross profit as a percentage of net revenue increased to 15.6% for the six months ended June 30, 2024 from 15.0% in the prior year period, primarily due to the increase in sales through our higher margin government channel, including higher margin new product introductions.

Selling, General and Administrative

AvKARE SG&A expense for the six months ended June 30, 2024 increased 9.6% as compared to the prior year period primarily due to higher sales-related expenses, partially offset by reduced logistic costs.

Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand, and borrowings under debt financing arrangements (as defined and discussed in Note 16. Debt in our 2023 Annual Report on Form 10-K). We have access to $416.9 million of available capacity under the Amended New Revolving Credit Facility and $28.0 million of available capacity under the Amended Rondo Revolving Credit Facility as of June 30, 2024. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control. Our primary uses of capital resources are to fund operating activities, including R&D expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, spending on production facility expansions, capital equipment, acquisitions, and legal settlements.

We estimate that we will invest approximately $60.0 million to $70.0 million during 2024 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology and facilities.

Debt Instruments

Over the next 12 months, we expect to make substantial payments, including monthly interest and quarterly principal amounts due for our Term Loan Due 2028, monthly interest and the remaining principal balance on our Term Loan Due 2025, monthly interest on our Amended New Credit Facility, and contractual payments for leased premises. Refer to Note 16. Debt, Note 18. Leases, and Commitments and Contractual Obligations under Part II, Item 7. Management’s Discussion and Analysis of

Financial Condition and Results of Operations in our 2023 Annual Report on Form 10-K for additional information on our indebtedness and leases, respectively. Also refer to Note 21. Subsequent Events in this Form 10-Q.

Settlement in Principle on Nationwide Civil Prescription Opioid Litigation

In late April 2024, we reached a nationwide settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed by Attorneys General, political subdivisions and Native American tribes. Refer to Note 17. Commitments and Contingencies for additional information.

Tax Receivable Agreement

In 2018, we entered into a tax receivable agreement (“TRA”) for which we were generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that we were deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to us (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A common stock and (ii) tax benefits attributable to payments made under the TRA. As part of the Reorganization (as defined in Note 1. Nature of Operations in our 2023 Annual Report on Form 10-K), the TRA was amended to reduce our future obligation to pay 85% of the realized tax benefits subject to the TRA to 75% of such realized benefits. As of both June 30, 2024 and December 31, 2023, the contingent TRA liability, including the impact of the amendment, was approximately $185.0 million.

The timing and amount of any payments under the TRA may vary, depending upon a number of factors including the timing and amount of our taxable income, and the corporate tax rate in effect at the time of realization of our taxable income (the TRA liability is determined based on a percentage of the corporate tax savings from the use of the TRA’s attributes). Because the Amneal Group (as defined in Item 1. Business in the Company’s 2023 Annual Report on Form 10-K) has exchanged all of its Amneal Common Units pursuant to the Reorganization, the primary remaining factor that could increase the contingent TRA liability is an increase in the effective tax rate. Since the combined rate for federal and state and local income taxes, as of June 30, 2024, has not changed significantly since December 31, 2023, the contingent TRA liability has not changed significantly during 2024. In addition, any future payments under the TRA may create additional basis adjustments, which may result in an additional layer of depreciation and amortization allocable to the Company, resulting in additional TRA payments. The timing and amount of payments may also be accelerated under certain conditions, such as a change of control or other early termination event, which could give rise to our obligation to make TRA payments in advance of tax benefits being realized. For further information, refer to Item 1A. Risk Factors in our 2023 Annual Report on Form 10-K and Note 5. Income Taxes in this Form 10-Q.

Tax-Related Distributions

Prior to the Reorganization, Amneal was obligated to make tax distributions to the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members”). During the six months ended June 30, 2023, the Company recorded net tax distributions to the Members of $29.7 million as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members.

In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the six months ended June 30, 2024 and 2023, we made cash tax distributions of $8.9 million and $5.8 million, respectively, to the AvKARE Sellers.

Omalizumab Exclusive License and Commercialization Agreement

Subsequent to June 30, 2024, we paid Kashiv Biosciences LLC (“Kashiv”), a related party, $20.0 million in connection with an exclusive license and commercialization agreement for Amneal to distribute and sell Omalizumab, a biosimilar to XOLAIR®, in the U.S. and India. Refer to Note 21. Subsequent Events for additional information.

Cash Balances

As of June 30, 2024, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

Cash Flows

The following table sets forth our summarized, consolidated cash flows for the six months ended June 30, 2024 and 2023 (in thousands):

Net cash provided by: Six Months Ended June 30, 2024 2023 Increase (Decrease) $%
Operating activities $35,247 $128,367 $(93,120) (72.5)%
Investing activities (26,225) (24,021) (2,204) 9.2%
Financing activities (58,241) (25,156) (33,085) 131.5%
Effect of exchange rate changes on cash (266) 165 (431) nm
Net (decrease) increase in cash, cash equivalents, and restricted cash $(49,485) $79,355 $(128,840) nm

nm - not meaningful

Cash Flows from Operating Activities

Net cash provided by operating activities was $35.2 million for the six months ended June 30, 2024 as compared to $128.4 million in the prior year period. The decrease in net operating cash flows for the six months ended June 30, 2024 as compared to the prior year period was primarily driven by (i) lower collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022, which benefited the six months ended June 30, 2023 and (ii) receipt of a $21.4 million upfront payment associated with the license agreement with Orion Corporation during the six months ended June 30, 2023, partially offset by (i) increased profitability adjusted for non-cash items, (ii) lower period over period payments associated with the Opana ER® antitrust litigation settlement and (iii) favorable working capital movements.

Cash Flows from Investing Activities

Net cash used in investing activities for the six months ended June 30, 2024 was $26.2 million as compared to $24.0 million in the prior year period. The period over period increase in net cash used in investing activities was primarily due to the payment of a sales-based milestone related to the licensing and supply agreement with mAbxience S.L. for its biosimilar candidate for Avastin® (bevacizumab), partially offset by (i) $5.0 million in proceeds from the sale of a subsidiary in India to a subsidiary of Kashiv (refer to Note 19. Related Party Transactions for additional information) and (ii) lower capital expenditures.

Cash Flows from Financing Activities

Net cash used in financing activities was $58.2 million for the six months ended June 30, 2024 as compared to $25.2 million in the prior year period. The period over period increase in net cash used in financing activities was primarily due to a year over year decrease in net debt of $55.1 million (including payments on the Sellers Notes) and an increase in employee payroll tax withholding on restricted stock unit vesting, partially offset by a period over period decrease in tax distributions to non-controlling interests of $26.7 million.

Commitments and Contractual Obligations

Our contractual obligations are set forth in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our 2023 Annual Report on Form 10-K. As of June 30, 2024, there have been no material changes to the disclosure presented in our 2023 Annual Report on Form 10-K.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of June 30, 2024.

Critical Accounting Policies and Estimates

For a discussion of our critical accounting policies and estimates, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2023 Annual Report on Form 10-K.

Recently Issued Accounting Standards

Recently issued accounting standards are discussed in Note 2. Summary of Significant Accounting Policies.

Market risk

As filed, 198 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There has not been any material change in our assessment of market risk as set forth in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, in our 2023 Annual Report on Form 10-K.

Controls and procedures

As filed, 2,875 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2024.

Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2024, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

Risk factors

As filed, 134 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the disclosures presented in our 2023 Annual Report on Form 10-K under Item 1A. Risk Factors.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-04-01 to 2024-06-30$701.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2024-01-01 to 2024-06-30$1.36bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2024-04-01 to 2024-06-30$451.8mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2024-01-01 to 2024-06-30$873.0mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2024-04-01 to 2024-06-30$249.9mus-gaap:GrossProfit
Gross profit6 months2024-01-01 to 2024-06-30$488.0mus-gaap:GrossProfit
Research and development3 months2024-04-01 to 2024-06-30$36.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2024-01-01 to 2024-06-30$75.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2024-04-01 to 2024-06-30$116.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2024-01-01 to 2024-06-30$229.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2024-04-01 to 2024-06-30$95.5mus-gaap:OperatingIncomeLoss
Operating income6 months2024-01-01 to 2024-06-30$84.7mus-gaap:OperatingIncomeLoss
Income tax3 months2024-04-01 to 2024-06-30$3.6mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2024-01-01 to 2024-06-30$9.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-04-01 to 2024-06-30$6.0mus-gaap:NetIncomeLoss
Net income6 months2024-01-01 to 2024-06-30−$85.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-04-01 to 2024-06-30$0.02us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2024-01-01 to 2024-06-30−$0.28us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-04-01 to 2024-06-30$0.02us-gaap:EarningsPerShareBasic
Basic EPS6 months2024-01-01 to 2024-06-30−$0.28us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-04-01 to 2024-06-30318,957,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2024-01-01 to 2024-06-30308,198,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2024-01-01 to 2024-06-30$35.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2024-01-01 to 2024-06-30$19.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2024-06-30$43.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-06-30$1.49bnus-gaap:AssetsCurrent
Total assetsAt period end2024-06-30$3.51bnus-gaap:Assets
Current liabilitiesAt period end2024-06-30$1.11bnus-gaap:LiabilitiesCurrent
Long-term debtAt period end2024-06-30$2.18bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2024-06-30$225.2mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2024-06-30−$57.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001723128-24-000032. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.